The pharmacological effects of isatin on Parkinson's disease
- Author:
Jian XU
1
;
Lei YIN
1
;
Hui-Hui XU
2
;
Xiao-Ling LI
2
;
Wang YUE
3
Author Information
- Publication Type:Journal Article
- Keywords: choline; dopamine; isatin; MAO-B; Parkinson's disease; protein activity modifier
- From: Chinese Pharmacological Bulletin 2023;39(10):1815-1818
- CountryChina
- Language:Chinese
- Abstract: Parkinson's disease (PD) is a kind of senile neurodegenerative disease. Dopaminergic drugs and anticholinergic drugs are the two major therapeutic drugs for PD. In the past several decades, great progress has been achieved on dopamines (DAs) and their synergists including monoamine oxidase B (MAO-B) inhibitors, catechol oxygen methyl transferase inhibitors, ergot and nonergot DA receptor agonists, DA precursor drugs, cannabis and isatin. Isatin is the inhibitor of endogenous specific anti-aging enzyme MAO-B, which has a variety of pharmacological activities. Moreover, the pharmacological mechanism of isatin may be associated with the regulatory functions of various protein activities.
